Research programme: KLH-conjugated vaccines - Matrivax

Drug Profile

Research programme: KLH-conjugated vaccines - Matrivax

Alternative Names: Keyhole limpet haemocyanin conjugated vaccine - Stellar; PSII-KLH conjugate

Latest Information Update: 22 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Guelph
  • Developer Matrivax
  • Class Bacterial polysaccharides; Bacterial vaccines; Conjugate-vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Clostridium-difficile-infections

Most Recent Events

  • 13 Mar 2017 Preclinical development is ongoing for Clostridium difficile infections in Canada and USA
  • 06 Mar 2017 Matrivax in-licenses PSII technology from Stellar Biotechnologies
  • 06 Mar 2017 Stellar Biotechnologies terminates its license with University of Guelph for PSII technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top